BostonGene, developer of the leading AI foundation model for cancer and the immune system, today announced the Company will present four posters at the Society for Immunotherapy of Cancer’s (SITC) 4...

BostonGene approach advances biomarker discovery, predicts immune response and toxicity and reveals resistance mechanisms across cancer types
WALTHAM, Mass.: BostonGene, developer of the leading AI foundation model for cancer and the immune system, today announced the Company will present four posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Anniversary Annual Meeting, taking place November 5-9, 2025 in National Harbor, Maryland. BostonGene will also exhibit at booth 319.
BostonGene will highlight research demonstrating the power of its omnimodal foundation AI to advance precision oncology. The studies showcase innovative approaches for identifying predictive biomarkers, optimizing patient selection in clinical trials, forecasting treatment-related toxicities through blood-based profiling and assessing the impact of combination therapies in B-cell non-Hodgkin lymphoma.
Scientific poster presentations details are below:
Friday, November 7
Abstract: 153
Title: Association of candidate tertiary lymphoid structures in baseline tumor tissue with response to ipilimumab in patients with metastatic castration-resistant prostate cancer (mCRPC)
Saturday, November 8
Abstract: 154
Title: Machine-learning tool Helenus enhances gene expression profiling to improve biomarker discovery in lung adenocarcinoma cohorts and advance the precision of immunotherapy
Abstract: 504
Title: Biological Mechanisms of Resistance to Macrophage Checkpoint Inhibitors in Relapsed B-cell Non-Hodgkin Lymphoma
Abstract: 1094
Title: Pre-treatment predictive modeling of immune-related adverse event risk in immune checkpoint blockade therapy: A multi-modal machine learning approach from a real-world setting (RADIOHEAD Cohort Study)
Abstracts will be published on November 4 in the Journal for ImmunoTherapy of Cancer (JITC), SITC’s official journal. To learn more or to schedule a meeting with BostonGene during SITC, please contact Hannah Oman at events@bostongene.com.
About BostonGene Corporation
BostonGene is redefining cancer patient care and drug development through the integration of omnimodal data and artificial intelligence. Built and validated through an extensive real-world clinical testing network, BostonGene’s Foundation Model of cancer and the immune system integrates genomic, transcriptomic, and immune data with clinical outcomes to generate biologically grounded, actionable insights. These insights enable biopharma partners to design and de-risk trials, identify novel targets, and optimize therapeutic response prediction across all stages of development while simultaneously improving patient care through clinically integrated innovation. For more information, visit www.BostonGene.com.
Fonte: Business Wire
Alaa Abdul Nabi, Vice President, Sales International at RSA presents the innovations the vendor brings to Cybertech as part of a passwordless vision for…
G11 Media's SecurityOpenLab magazine rewards excellence in cybersecurity: the best vendors based on user votes
Always keeping an European perspective, Austria has developed a thriving AI ecosystem that now can attract talents and companies from other countries
Successfully completing a Proof of Concept implementation in Athens, the two Italian companies prove that QKD can be easily implemented also in pre-existing…
Deepgram, the world’s most realistic and real-time Voice AI platform, today announced integration of its enterprise-grade speech-to-text (STT) and text-to-speech…
Deepgram, the world’s most realistic and real-time Voice AI platform, today announced native integration with Amazon SageMaker AI, delivering streaming,…
NeurIPS 2025, Booth #732 – MathWorks, the leading developer of mathematical computing software, will showcase how engineers and scientists can use MATLAB®…
In Lower West Side, Chicago section, first bullet point should read: Total BFCM Weekend Volume: $8.4M (instead of Total BFCM Weekend Volume: $49M). The…